Novavax (NASDAQ:NVAX) Trading 6.1% Higher

Shares of Novavax, Inc. (NASDAQ:NVAX) traded up 6.1% during trading on Friday . The company traded as high as $13.75 and last traded at $13.75. 1,095,487 shares traded hands during trading, a decline of 91% from the average session volume of 11,775,267 shares. The stock had previously closed at $12.96.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. HC Wainwright restated a “buy” rating and set a $19.00 price target on shares of Novavax in a research note on Monday, May 13th. JPMorgan Chase & Co. raised shares of Novavax from an “underweight” rating to a “neutral” rating in a report on Friday, May 10th. TD Cowen lifted their price objective on shares of Novavax from $5.00 to $10.00 and gave the stock a “hold” rating in a report on Monday, May 13th. B. Riley lifted their price objective on shares of Novavax from $11.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, May 23rd. Finally, Bank of America lifted their price objective on shares of Novavax from $12.00 to $18.00 and gave the stock a “neutral” rating in a report on Friday, June 14th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Novavax has an average rating of “Hold” and an average target price of $19.00.

Novavax Stock Up 0.8 %

The stock’s fifty day moving average is $13.44 and its two-hundred day moving average is $7.64.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.01). The company had revenue of $93.90 million for the quarter, compared to the consensus estimate of $71.32 million. The business’s revenue was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.41) earnings per share. As a group, analysts predict that Novavax, Inc. will post 0.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Novavax

In other Novavax news, insider Filip Dubovsky sold 47,312 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $13.90, for a total transaction of $657,636.80. Following the sale, the insider now directly owns 38,953 shares of the company’s stock, valued at $541,446.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director James F. Young sold 7,500 shares of the company’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $13.72, for a total transaction of $102,900.00. Following the sale, the director now directly owns 69,260 shares in the company, valued at $950,247.20. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Filip Dubovsky sold 47,312 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $13.90, for a total transaction of $657,636.80. Following the completion of the transaction, the insider now owns 38,953 shares in the company, valued at $541,446.70. The disclosure for this sale can be found here. Insiders have sold a total of 62,312 shares of company stock valued at $866,212 over the last three months. 0.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Swedbank AB bought a new position in shares of Novavax in the first quarter worth approximately $26,000. Herr Investment Group LLC bought a new position in shares of Novavax in the first quarter worth approximately $48,000. Alpine Global Management LLC purchased a new stake in Novavax in the first quarter worth approximately $49,000. Ameritas Investment Partners Inc. boosted its stake in Novavax by 31.6% in the first quarter. Ameritas Investment Partners Inc. now owns 11,298 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 2,711 shares in the last quarter. Finally, Edgestream Partners L.P. boosted its stake in Novavax by 23.7% in the first quarter. Edgestream Partners L.P. now owns 12,753 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 2,447 shares in the last quarter. 53.04% of the stock is currently owned by institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.